Gracell Biotechnologies Inc. (GRCL) — Net Asset Quality Index
Gracell Biotechnologies Inc. (GRCL) has a Net Asset Quality Index of 85.8% as of September 2023. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $1.89 Billion minus total liabilities of $268.86 Million yields net assets of $1.62 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of Gracell Biotechnologies Inc. for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Gracell Biotechnologies Inc. Net Asset Quality Index Over Time (2018–2022)
This chart shows how Gracell Biotechnologies Inc.'s Net Asset Quality Index has evolved across 5 annual periods from 2018 to 2022. As of September 2023, the index stands at 85.8%, representing net assets of $1.62 Billion against total assets of $1.89 Billion USD. For live market cap and overall valuation, see Gracell Biotechnologies Inc. stock valuation.
Annual Net Asset Quality Index for Gracell Biotechnologies Inc. (2018–2022)
The table below presents the year-by-year Net Asset Quality Index for Gracell Biotechnologies Inc. from 2018 to 2022, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check GRCL strategic asset allocation to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 83.1% | $1.38 Billion | $1.66 Billion | $280.51 Million | ▼ -5.6 pp |
| 2021 | 88.7% | $1.83 Billion | $2.06 Billion | $232.77 Million | ▲ +3.8 pp |
| 2020 | 84.9% | $819.66 Million | $964.95 Million | $145.29 Million | ▲ +23.0 pp |
| 2019 | 61.9% | $255.36 Million | $412.22 Million | $156.86 Million | ▲ +60.3 pp |
| 2018 | 1.6% | $2.38 Million | $148.52 Million | $146.13 Million | — |